Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 27 - Drugs for disorders of the senses
Patents for A61P 27 - Drugs for disorders of the senses (53,017)
11/2000
11/23/2000CA2374053A1 Secreted polypeptides and corresponding polynucleotides
11/23/2000CA2373191A1 Full-length molecules expressed in human tissues
11/23/2000CA2372934A1 Aromatic sulfone hydroxamic acid metalloprotease inhibitor
11/23/2000CA2372926A1 143 human secreted proteins
11/23/2000CA2372426A1 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/22/2000EP1054017A1 Salts of thrombin inhibitors
11/22/2000EP1053750A1 Use of proteasome-inhibitor for the induction of programmed cell death (apoptosis)
11/22/2000EP1053233A1 Hydroxamic and carboxylic acid derivatives
11/22/2000EP1053226A1 Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
11/22/2000EP1053003A1 Compositions and methods for separating lens epithelial cells and preventing posterior capsular opacification
11/22/2000EP0701443B2 Terfenadine metabolites and their optically pure isomers for treating allergic disorders
11/22/2000EP0669936B1 Mercaptoacetylamide bicyclic lactam derivatives useful as inhibitors of enkephalinase and ace
11/22/2000EP0639078B1 Use of silicone/fluorosilicone copolymer oil for the manufacture of a medicament for treating eye disorders
11/22/2000CN1273851A Chinese medicine for treating intraocular hemorrhage
11/22/2000CN1058626C Application of sinomenine in prepn. of medicine for immunological eye diseases
11/22/2000CN1058617C Cockscomb beverage
11/21/2000US6150526 Piperidine derivative having renin inhibiting activity
11/21/2000US6150413 Treatment of dermatological, rheumatic, respiratory, cardiovascular, bone and ophthalmological disorders, as well as mammalian skin and hair conditions; 4-(4-(biphenyl-2-yl)but-3-en-1-ynyl)benzoic acid, for example
11/21/2000US6150411 Treating dyslexia by administering to a subject docosahexaenoic acid (dha)
11/21/2000US6150407 In a tissue or organ by contacting with a compound of given formula such as methyl-3,5-diiodo-4-(4'-methoxyphenoxy)benzoate; reducing the level of tumor necrosis factor alpha
11/21/2000US6150389 Antidepressants; treating elevated intraocular pressure, e.g., glaucoma; antidiabetic agents for non-insulin dependent diabetes, sexual disorders, e.g., male impotence and obesity; e.g. trans-2-(3-phenyl-bicyclo(2.2.1)heptyl)-2-aminooxazoline
11/21/2000US6150370 1,3-dinitrocyclic compound treats numerous diseases caused by undesired metalloprotease activity, such as tumor metastasis, osteoarthritis, rheumatoid arthritis, skin inflammation, ulcerations, and periodontitis
11/21/2000US6150340 RNA-dependent amidotransferase from Staphylococcus aureus
11/21/2000US6150132 Vector coding polypeptides for the diagnosis and treatment of allergies and atherosclerosis; for the prevention of graft ejection and injuries to stem cell caused by anticarcinogenic agents
11/21/2000US6150101 Methods of identifying a composition that alters connective tissue growth factor expression
11/21/2000US6149931 Applying over and around retinal break a non-toxic polymer formulation comprising polymer precursor that is a poly(ethylene glycol) based polymer precursor, and transforming the polymer formulation into a gel-like coat
11/16/2000WO2000068380A2 Extracellular matrix and adhesion-associated proteins
11/16/2000WO2000068267A1 LOW-DOSE IL-1β-INDUCED PHOTORECEPTOR CELL RESCUE WITHOUT RETINAL DYSPLASIA
11/16/2000WO2000068243A1 Methods using mechanisms of action of aroa
11/16/2000WO2000068224A1 Substituted benzolactam compounds
11/16/2000WO2000068215A1 Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use
11/16/2000WO2000068198A2 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/16/2000WO2000067738A2 The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders
11/16/2000WO2000067626A2 Oat extracts: refining, compositions and methods of use
11/16/2000WO2000041669A3 Benzimidazole vascular damaging agents
11/16/2000WO2000041469A3 β-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS
11/16/2000WO2000037025A3 Antibodies to truncated vegf-d and uses thereof
11/16/2000WO2000035432A3 Improved viscoelastic compositions and methods of use
11/16/2000WO2000034468A3 Muc-1 antagonists and methods of treating immune disorders
11/16/2000WO2000027887A3 Cross-linked hyaluronic acids and medical uses thereof
11/16/2000WO2000027377A3 Phosphinate peptide analogs for the treatment of fibrotic disorders
11/16/2000WO2000026370A3 Adenine nucleotide translocator (ant) fusion proteins and uses thereof
11/16/2000WO2000026224A3 Novel macrolide antibiotics
11/16/2000WO2000018316A3 Sustained release, and comfortable ophthalmic composition and method for ocular therapy
11/16/2000WO2000009103A3 N-linked sulfonamides of n-heterocyclic carboxylic acids or isosteres for vision and memory disorders
11/16/2000DE19920247A1 Arzneimittel mit einem Gehalt an Verbindungen mit einem Stickstoff-Sauerstoff-Heterocyclus als Wirkstoff und ihre Verwendung Medicaments with an amount of compounds having a nitrogen-oxygen heterocycle as active ingredient and their use
11/16/2000CA2373178A1 The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders
11/16/2000CA2373079A1 Substituted benzolactam compounds
11/16/2000CA2372815A1 Extracellular matrix and adhesion-associated proteins
11/16/2000CA2372738A1 Low-dose il-1.beta.-induced photoreceptor cell rescue without retinal dysplasia
11/16/2000CA2369333A1 Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use
11/16/2000CA2369323A1 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/15/2000EP1051655A1 Methods and apparatus for accelerated orthokeratology
11/15/2000EP1051511A1 Methods of identifying modulators of kinases responsive to stress
11/15/2000EP1051431A1 Thrombin inhibitors
11/15/2000EP1051428A1 Human cystatin f
11/15/2000EP1051403A1 Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them
11/15/2000EP1051395A1 Hydroxamic and carboxylic acid derivatives
11/15/2000EP1051165A2 Mitochondria protecting agents for treating mitochondria associated diseases
11/15/2000EP1051155A1 Nasal solutions
11/15/2000CN1273534A Method for treating neurological deficits
11/14/2000US6147255 Topical and systemic treatment of dermatological complaints associated with keratinization disorder which has effect on differentiation and on proliferation
11/14/2000US6147224 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
11/14/2000US6147188 Irreversible cathepsin or calpain inhibitors
11/14/2000US6147050 5-lipoxygenase-activating protein II
11/14/2000US6146630 Inhibitors for the adhesion of lymphocytes to glandular cells
11/14/2000US6146622 Use of certain anionic amino acid based surfactants to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions
11/09/2000WO2000066731A2 Recombinant laminin 5
11/09/2000WO2000066631A1 SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS FOR TGFβ¿1?
11/09/2000WO2000066630A1 DNA ENCODING SNORF36a AND SNORF36b RECEPTORS
11/09/2000WO2000066572A1 Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents
11/09/2000WO2000066522A1 Glucocorticoid receptor modulators
11/09/2000WO2000066161A1 Preventives / remedies / progression inhibitors for simplex retinopathy or preproliferating retinopathy
11/09/2000WO2000066148A1 Novel proteins
11/09/2000WO2000066144A2 Monthly doses of glycopeptide antibiotics for treatment of streptococcus pneumoniae infections
11/09/2000WO2000066139A2 Biochemical methods that eliminate corneal scars, opacification and haze
11/09/2000WO2000066122A1 Use of macrolide compounds for the treatment of dry eye
11/09/2000WO2000066107A2 Antimalarian agents for the treatment of asthma
11/09/2000WO2000066094A2 Use of compounds with a nitrogen-oxygen heterocycle as anti-infectious agents
11/09/2000WO2000066086A1 Anti-inflammatory bioactive glass particulates
11/09/2000WO2000032584A3 Nonsteroidal antiinflammatories
11/09/2000WO2000026367A3 Therapeutics and diagnostics for ocular abnormalities
11/09/2000WO2000023565A3 Novel neuropilin/growth factor binding and uses thereof
11/09/2000WO2000019989A3 Use of catechol derivatives as proteinase inhibitors
11/09/2000WO2000010968A3 Novel aryl sulphonamide amino acid esters and analogues
11/09/2000CA2372923A1 Dna encoding snorf36a and snorf36b receptors
11/09/2000CA2372790A1 Monthly doses for treatment of streptococcus pneumonia infections
11/09/2000CA2372448A1 Use of macrolide compounds for the treatment of dry eye
11/09/2000CA2372173A1 Glucocorticoid receptor modulators
11/09/2000CA2371757A1 Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents
11/09/2000CA2370504A1 Biochemical methods that eliminate corneal scars, opacification and haze
11/09/2000CA2370304A1 Specific antibodies and antibody fragments for tgf.beta.1
11/09/2000CA2369526A1 Use of compounds with a nitrogen-oxygen heterocycle as anti-infectious agents
11/08/2000EP1050304A1 Liquid ophthalmic preparations
11/08/2000EP1050301A1 Medicinal compositions
11/08/2000EP1049780A1 Adenine nucleotide translocator (ant) fusion proteins and uses thereof
11/08/2000EP1049677A1 Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
11/08/2000EP1049483A1 Method for treating inflammatory diseases using heat shock proteins
11/08/2000EP1049471A1 Compositions and methods for treating atopic dermatitis, angioedema and other disorders using antihistamines and glucocorticoids
11/08/2000EP1049467A1 Celecoxib compositions
1 ... 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 ... 531